COVID-19

COVID-19 vaccines: under evaluation

The European Medicines Agency (EMA) is evaluating potential COVID-19 vaccines to enable the distribution of promising vaccines in the European Union (EU) as soon as possible. 

COVID-19 vaccines under rolling review

EMA's Committee for Medicinal Products for Human Use (CHMP) is evaluating the following COVID-19 vaccines:

VaccineVaccine developerStart of rolling reviewMore information
CVnCoVCureVac AG
12/02/2021
NVX-CoV2373
Novavax CZ AS
03/02/2021
Sputnik V (Gam-COVID-Vac)Russia’s Gamaleya National Centre of Epidemiology and Microbiology04/03/2021EMA starts rolling review of the Sputnik V COVID-19 vaccine
COVID-19 Vaccine (Vero Cell) InactivatedSinovac Life Sciences Co., Ltd04/05/2021EMA starts rolling review of COVID-19 Vaccine (Vero Cell) Inactivated
VidprevtynSanofi Pasteur20/07/2021

For more information on the expedited evaluation procedure EMA is applying for COVID-19 vaccines, including the rolling review, see:

COVID-19 vaccines under conditional marketing authorisation evaluation

There are no marketing authorisation applications currently under evaluation by EMA’s CHMP.

For more information on the expedited evaluation procedure EMA is applying for COVID-19 vaccines, including the conditional marketing authorisation, see:

Topics

How useful was this page?

Add your rating
Average
18 ratings
8 ratings
7 ratings
10 ratings
52 ratings